AKRO vs. MORF, RCUS, ANIP, GYRE, KNSA, XNCR, PTGX, DVAX, ARDX, and DAWN
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Morphic (MORF), Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Gyre Therapeutics (GYRE), Kiniksa Pharmaceuticals (KNSA), Xencor (XNCR), Protagonist Therapeutics (PTGX), Dynavax Technologies (DVAX), Ardelyx (ARDX), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.
Morphic (NASDAQ:MORF) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Akero Therapeutics' return on equity of -22.93% beat Morphic's return on equity.
In the previous week, Akero Therapeutics had 22 more articles in the media than Morphic. MarketBeat recorded 24 mentions for Akero Therapeutics and 2 mentions for Morphic. Morphic's average media sentiment score of 0.35 beat Akero Therapeutics' score of -0.25 indicating that Akero Therapeutics is being referred to more favorably in the news media.
Morphic currently has a consensus price target of $51.50, indicating a potential upside of 79.94%. Akero Therapeutics has a consensus price target of $37.71, indicating a potential upside of 91.93%. Given Morphic's stronger consensus rating and higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Morphic.
Akero Therapeutics has lower revenue, but higher earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Akero Therapeutics received 18 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 60.76% of users gave Akero Therapeutics an outperform vote while only 59.54% of users gave Morphic an outperform vote.
94.3% of Morphic shares are held by institutional investors. 28.1% of Morphic shares are held by company insiders. Comparatively, 9.7% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Morphic has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500.
Summary
Akero Therapeutics beats Morphic on 10 of the 16 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akero Therapeutics Competitors List
Related Companies and Tools
